Director, Florida Hospital Diabetes Institute Senior Investigator, Translational Research Institute Adjunct Professor, Sanford-Burnham Medical Research Institute
Internal Medicine
Dr. Richard E. Pratley, MD
|
|
Give Review
Richard E. Pratley practices Internal Medicine. He graduated from Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63 in research and 85 in primary care medicine Doctor Richard E. Pratley, MD is also a published doctor. He has 53 publication published. The most recent publication is: COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES. Doctor Richard E. Pratley, MD is registered with Medicare and accepts Medicare payments.
Publications
- COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 Diabetes.
- The Impact of Diabetes and Diabetes Medications on Bone Health.
- HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 Diabetes inadequately controlled with metformin wit...
- Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 Diabetes: a randomize...
- The efficacy and effectiveness of drugs for Diabetes: how do clinical trials and the real world compare?
- Sweet Taste Receptors Regulate Basal Insulin Secretion and Contribute to Compensatory Insulin Hypersecretion During the Development of Diabetes in Male Mice.
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 Diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, mul...
- The early treatment of type 2 Diabetes.
- Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 Diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a ra...
- Cardiovascular Safety of the Dipetidyl Peptidase-4 inhibitor Alogliptin in Type 2 Diabetes Mellitus.
- Obesity and asthma: an inflammatory disease of adipose tissue not the airway.
- Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Di...
- Measurement of Altered A?PP Isoform Expression in Frontal Cortex of Patients with Alzheimer's Disease by Absolute Quantification Real-Time PCR.
- Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes ???65 and <65 Years of Age: A Poo...
- Efficacy of Anthiyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program.
- Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation.
- Adipose tissue dysfunction in polycystic ovary syndrome.
- Does the metabolic syndrome carry additional risk for myocardial infarction?
- Sexually dimorphic diet-induced insulin resistance in obese tissue inhibitor of metalloproteinase-2 (TIMP-2)-deficient mice.
- Central and peripheral endocannabinoids and cognate acylethanolamides in humans: association with race, adiposity, and energy expenditure.
- GIP: an inconsequential incretin or not?
- Ezetimibe/simvastatin or atorvastatin for the treatment of hypercholesterolemia in patients with the metabolic syndrome: the VYMET study.
- Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
- Efficacy and safety of incretin-based therapies in patients with type 2 Diabetes mellitus.
- Weight loss and diets: which diet works best?
- Expanding treatment options for type 2 Diabetes: the old and the new.
- Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 Diabetes.
- Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 Diabetes.
- The cannabinoid CB1 receptor is expressed in pancreatic delta-cells.
- Amyloid precursor protein expression is upregulated in adipocytes in obesity.
- Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion.
- LAP-BAND or medical therapy for metabolic syndrome?
- Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 Diabetes.
- Management of type 2 Diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy.
- The DREAM Trial: using ramipril and rosiglitazone to prevent Diabetes.
- Metabolic syndrome: why the controversy?
- Abdominal obesity and cardiovascular disease risk: the emerging role of the adipocyte.
- Insulin resistance increases PAI-1 in the heart.
- The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 Diabetes.
- Beta-cell function in mild Type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide.
- The evolving role of inflammation in obesity and the metabolic syndrome.
- Endogenous glucose production, insulin sensitivity, and insulin secretion in normal glucose-tolerant Pima Indians with low birth weight.
- Taste preferences and body weight changes in an obesity-prone population.
- Effects of improving insulin sensitivity on nontraditional cardiovascular risk factors in patients with type 2 Diabetes.
- Progression from IGT to type 2 Diabetes mellitus: the central role of impaired early insulin secretion.
- High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 Diabetes.
- Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whol...
- Sex differences in the human brain's response to hunger and satiation.
- UCP5/BMCP1 transcript isoforms in human skeletal muscle: relationship of the short-insert isoform with lipid oxidation and resting metabolic rates.
- The quality of fat in the diet and its impact on insulin sensitivity.
- High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 Diabetes.
- Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 Diabetes and a baseline A1C <8.0%.
Conditions Treated
- Diabetes Type 1
- Diabetes Type 2
Doctors Specialties
- Geriatric Medicine
- Internal Medicine
Accepted Insurances
Education
-
Johns Hopkins University -
University of Michigan Hospitals and Health Centers -
Wayne State University School of Medicine
Hospital
-
Florida Hospital
Drug Facts
| NPI NUMBER | 1194837476 | |
| NPPES Provider LastName | PRATLEY | |
| NPPES Provider FirstName | RICHARD | |
| NPPES Provider ZIPCode | 328045505 | |
| NPPES Provider State | FL | |
| Specialty Description | Geriatric Medicine | |
| Total Claim Count | 651.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1194837476 |
| Last Name Of The Provider | PRATLEY |
| First Name Of The Provider | RICHARD |
| View All |
Similar Doctors
|
Dr. Lakshman Rao Nagalla, MD |
|
|
Dr. Ingrid T. Fiallo, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bolanle Akakabota, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Beena S. Patel, MD |
|
|
Dr. Frank H. Leiva, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ashok K. Khanna, MD |
|
|
Dr. Omid H. Zad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vijayalakshmi Polavarapu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew R. Novak, MD |
|
|
Dr. Stephanie S. Prada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arnold W. Fleischmann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter W. Weissgerber, MD
This Doctor is OpenDoctor Recommended.
|